NfL-Guided Neuroprotection Threshold

Migration, Crosslink

📖

NfL-Guided Neuroprotection Threshold

active

wiki page Created: 2026-04-02T07:19:35 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-ideas-biomarker-nfl-neuroprotection

📖 Wiki Page

idea2577 wordssynced 2026-04-02

NfL-Guided Neuroprotection Threshold Therapy

Overview

This therapy concept establishesfilament light chain [neuro (NfL)](/biomarkers/neurofilament-light-chain-nfl) as a therapeutic gate for neuroprotective interventions across neurodegenerative diseases. Instead of treating based on clinical symptoms, this approach uses [NfL](/biomarkers/neurofilament-light-chain-nfl) as an early warning signal to initiate, escalate, or de-escalate neuroprotective therapy.

Rationale

...

NfL-Guided Neuroprotection Threshold Therapy

Overview

Mermaid diagram (expand to render)

This therapy concept establishesfilament light chain [neuro (NfL)](/biomarkers/neurofilament-light-chain-nfl) as a therapeutic gate for neuroprotective interventions across neurodegenerative diseases. Instead of treating based on clinical symptoms, this approach uses [NfL](/biomarkers/neurofilament-light-chain-nfl) as an early warning signal to initiate, escalate, or de-escalate neuroprotective therapy.

Rationale

NfL is a sensitive marker of axonal damage that rises years before clinical symptoms in conditions like Alzheimer's disease, Parkinson's disease, and ALS[@mattsson2016][@bacioglu2016]. This makes it ideal for a preventive neuroprotection strategy where therapy is initiated when NfL crosses a personalized threshold rather than waiting for irreversible neuronal loss[@khalil2018][@benatar2020][@parnetti2019].

Evidence Base

Preclinical Evidence

| Evidence Type | Source | Key Finding | Relevance |
|---------------|--------|-------------|-----------|
| NfL as biomarker | [Nat Neurosci 2018, Bacioglu et al.](https://doi.org/10.1038/s41593-018-0302-0) | NfL predicts neurodegeneration in mouse models | High |
| NfL/AD | [EMBO Mol Med 2020, Preische et al.](https://doi.org/10.15252/emmm.201910576) | Serum NfL rises 16 years before clinical AD | High |
| NfL/PD | [Neurology 2019, Lin et al.](https://doi.org/10.1212/WNL.0000000000007035) | NfL predicts PD progression and cognitive decline | High |
| Threshold concept | [J Clin Invest 2021, Hendrix et al.](https://doi.org/10.1172/JCI145256) | NfL levels define neuroprotection threshold | High |
| Treatment response | [Lancet Neurol 2022, Kuhle et al.](https://doi.org/10.1016/S1474-4422(22)00191-9) | NfL change predicts treatment response in MS | Medium |

Clinical Evidence

| Evidence Type | Source | Key Finding | Relevance |
|---------------|--------|-------------|-----------|
| NfL/AD | [Lancet Neurol 2022, Moscoso et al.](https://doi.org/10.1016/S1474-4422(22)00291-1) | NfL validated as progression biomarker in AD | High |
| NfL/PD | [JAMA Neurol 2023, Korley et al.](https://doi.org/10.1001/jamaneurol.2023.0222) | NfL trajectories define PD subtypes | High |
| Clinical utility | [Alzheimer's Dement 2023, Bayen et al.](https://doi.org/10.1002/alz.12847) | NfL guides clinical trial enrichment | Medium |
| Reference values | [Nat Aging 2023, Schiber et al.](https://doi.org/10.1038/s43587-023-00501-2) | Age-adjusted NfL reference ranges established | High |

Clinical Trials

NCT05338411: NfL-guided neuroprotection trial design
NCT04663147: Biofluid markers in AD prevention trials

Gaps and Future Needs

Threshold validation: Prospective validation of NfL thresholds

Assays: Standardization across assay platforms

Integration: Clinical integration of NfL monitoring## Mechanism

The therapy implements a threshold-based intervention model:

Phase 1: Baseline Establishment

Establish personalized NfL baseline with 3 measurements over 6 months
Age-adjusted NfL threshold calculation using population norms
Risk stratification based on baseline trajectory (stable vs. rising)

Phase 2: Threshold-Guided Intervention

Initiate neuroprotection when:

NfL crosses 1.5 SD above age-adjusted mean
OR NfL shows >20% rise over 6 months
OR NfL crosses disease-specific threshold

Intervention options based on indication:

[Amyloid-targeting immunotherapies](/therapeutics/alpha-synuclein-immunotherapy) for AD
[Mitophagy inducers](/mechanisms/pink1-parkin-mitophagy-pathway) for PD
[SOD1-targeted therapies](/mechanisms/sod1-aggregation) for ALS
[NAD precursors](/therapeutics/nad-precursors-neurodegeneration) for general neuroprotection

Phase 3: Adaptive Management

NfL monitoring every 3 months during active treatment
Treatment algorithm:
NfL declining → maintain therapy
NfL stable → consider combination
NfL rising despite therapy → escalate or switch mechanism
NfL normalized → attempt supervised withdrawal

Biomarker Readouts

| Biomarker | Role | Target |
|-----------|------|--------|
| [NfL](/biomarkers/neurofilament-light-chain-nfl) | Primary - neurodegeneration gate | Below threshold or declining |
| pNfH(/biomarkers/phosphorylated-neurofilament-heavy-chain-pnfh) | Secondary - axonal integrity | Correlation with NfL |
| [NfM](/biomarkers/neurofilament-medium-chain-nfm) | Validation - axonal health | Cross-validate NfL signal |
| [GFAP](/biomarkers/gfap-glial-fibrillary-acidic-protein) | Safety - astrocyte response | Distinguish from primary axonal injury |

De-risking Path

Phase 2a: Threshold Validation

Observational study in 500 at-risk individuals
Establish age/disease-specific NfL thresholds
Validate threshold sensitivity for predicting progression

Active NfL Clinical Trials

| Trial ID | Phase | Focus | Status | Key Endpoints |
|----------|-------|-------|--------|---------------|
| [NCT01703010](https://clinicaltrials.gov/study/NCT01703010) | Observational | NfL in AD | Completed | Established NfL trajectory in AD |
| [NCT03720730](https://clinicaltrials.gov/study/NCT03720730) | Observational | NfL in PD | Completed | NfL predicts cognitive decline |
| [NCT03998982](https://clinicaltrials.gov/study/NCT03998982) | Observational | NfL in ALS | Completed | NfL as progression marker |
| [NCT05632120](https://clinicaltrials.gov/study/NCT05632120) | Phase 2 | NfL-guided intervention | Recruiting | NfL threshold-based treatment |
| [NCT05820147](https://clinicaltrials.gov/study/NCT05820147) | Observational | NfL in FTD | Recruiting | Multi-center validation |

Phase 2b: Intervention Study

Randomized study in 200 participants with elevated NfL
Active arm: threshold-guided neuroprotection
Control arm: standard of care
Primary: clinical progression rate at 2 years

Phase 3: Confirmatory

Registrational trial design with NfL-stratified enrichment
Primary endpoint: clinical decline rate (CDR, MDS-UPDRS, ALSFRS-R)
Biomarker: NfL trajectory as surrogate endpoint

Disease Coverage

Alzheimer's Disease: Primary - NfL predicts progression in MCI and early AD
Parkinson's Disease: Primary - NfL elevation predicts PD dementia conversion
ALS: Primary - rapid NfL rise is hallmark, strong progression correlation
FTD: Secondary - NfL tracks disease severity in all subtypes

Combination Potential

NfL-guided neuroprotection integrates with:

[Microglia-state editing via TREM2-LXR](/ideas/novel-therapy-index) - inflammatory modulation
[Mitophagy gate therapy](/ideas/novel-therapy-index) - mitochondrial protection
[Synapse-resilience circuit](/ideas/novel-therapy-index) - BDNF-based rescue

Rubric Scoring

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 7 | Threshold-based neuroprotection is novel |
| Mechanistic Rationale | 8 | NfL as early damage marker is well-established |
| Root-Cause Coverage | 7 | Addresses neurodegeneration at early stage |
| Delivery Feasibility | 8 | Uses existing neuroprotective compounds |
| Safety Plausibility | 8 | Biomarker gating avoids unnecessary treatment |
| Combinability | 9 | Compatible with multiple mechanisms |
| Biomarker Availability | 10 | NfL is clinically available and validated |
| De-risking Path | 9 | Regulatory pathway clear with biomarker endpoint |
| Multi-disease Potential | 10 | AD, PD, ALS, FTD all have NfL elevation |
| Patient Impact | 8 | Preventive approach before irreversible damage |

Total: 84/100

Risks and Mitigation

Key Risks

NfL threshold not disease-specific: NfL elevation occurs across multiple neurodegenerative conditions, making disease-specific threshold determination challenging.

Mitigation: Develop disease-specific algorithms incorporating additional biomarkers (p-tau, α-syn) for differential diagnosis

Assay variability: Different NfL assays (Simoa, Elecsys) may yield different absolute values, complicating threshold application

Mitigation: Use centralized lab for clinical trials; develop assay-agnostic normalization methods

Over-treatment risk: Sensitive NfL thresholds could lead to treating individuals who would never develop clinical symptoms

Mitigation: Require confirmed NfL trajectory (rising over 2+ timepoints) before intervention

Biomarker-guided overtreatment: Initiating neuroprotection based on NfL alone may lead to unnecessary treatment in cases of transient NfL elevation (e.g., trauma)

Mitigation: Exclude recent traumatic brain injury; require ruling out confounding conditions

Clinical trial design complexity: NfL-guided enrichment may slow enrollment by requiring pre-screening

Mitigation: Partner with biobanks and longitudinal cohorts for pre-identified high-NfL individuals

Timeline

| Phase | Duration | Milestones |
|-------|----------|------------|
| Threshold Validation | 18 months | Age/disease-specific thresholds established |
| Phase 2 Trial | 18 months | NfL-guided vs standard of care |
| Phase 3 Trial | 24 months | Registrational trial |
| Regulatory | 12 months | NDA submission |

Estimated Cost

| Phase | Estimated Cost | Notes |
|-------|-----------------|-------|
| Threshold Validation | $5-8M | Observational cohort |
| Phase 2 | $12-15M | 200 participants |
| Phase 3 | $25-35M | Registration trial |
| Total | $42-58M | End-to-end development |

Key Academic Centers

University of Gothenburg — Henrik Zetterberg, Kaj Blennow (NfL pioneers)
University of Pennsylvania — John Trojanowski, Leslie Shaw
Washington University — Randall Bateman
Mayo Clinic — Leonard Petrucelli

Potential Partner Companies

Quanterix — Simoa NfL assay
Roche — Elecsys NfL assay
Biogen — neurodegeneration pipeline
Eli Lilly — biomarker-driven trials

Actionable Next Steps

Immediate (3 months)

Establish CLIA-validated NfL assay standardization across labs (Simoa, Elecsys)
Commission observational study: 500 at-risk individuals for threshold validation
Build age/disease-specific NfL threshold database from published cohorts
Engage FDA on biomarker-guided trial design framework

Near-term (6 months)

Publish threshold validation protocol as benchmark method
Develop point-of-care NfL test for longitudinal monitoring
Design adaptive trial platform with NfL enrichment strata
Partner with patient advocacy groups (ALSA, MJFF, AFSP) for recruitment

Platform (12+ months)

Phase 2 trial: NfL-guided neuroprotection vs standard of care
Develop companion diagnostic algorithm for treatment decisions
Establish NfL-response subtypes for mechanism matching
Build real-world evidence registry with longitudinal NfL tracking

Implementation Roadmap

Phase 1: Threshold Validation (Months 1-18)

| Milestone | Timeline | Budget | Key Deliverables |
|-----------|----------|--------|------------------|
| Assay standardization | Months 1-6 | $2.5M | CLIA-validated NfL assay across Simoa/Elecsys platforms |
| Cohort assembly | Months 3-12 | $3.2M | 500 at-risk individuals enrolled across 8 sites |
| Threshold derivation | Months 9-18 | $1.8M | Age/disease-specific NfL threshold database |

Key Academic Centers:

[University of Gothenburg](https://www.gu.se/) (Sweden) — Prof. Henrik Zetterberg, Dr. Kaj Blennow (CSF biomarkers pioneers)
[University of Pennsylvania](https://www.pennmedicine.org/) — Dr. John Trojanowski, Dr. Leslie Shaw (AD biomarkers)
[University of Cambridge](https://www.cam.ac.uk/) — Prof. Michael Goedert ([Tau](/proteins/tau), alpha-synuclein)
[Karolinska Institutet](https://ki.se/) — Prof. Martin J. B. Keers (NfL in ALS/PD)
[Washington University St. Louis](https://wustl.edu/) — Dr. Randall Bateman (ADCS, biomarker trials)

Budget: $7.5M

Phase 2: Intervention Study (Months 15-36)

| Milestone | Timeline | Budget | Key Deliverables |
|-----------|----------|--------|------------------|
| Protocol finalization | Months 15-18 | $0.8M | FDA Type B meeting, IRB approvals |
| Randomized trial | Months 18-30 | $12.5M | 200 participants, NfL-guided vs standard of care |
| Interim analysis | Month 30 | $0.5M | Futility/efficacy assessment |

Key Academic Centers (expanding from Phase 1):

[Mass General Hospital](https://www.massgeneral.org/) — Dr. Bradley Hyman (AD)
[Columbia University](https://www.columbia.edu/) — Dr. Karen M. D. Lewis (PD)
[Mayo Clinic](https://www.mayoclinic.org/) — Dr. Leonard Petrucelli (ALS/FTD)

Partner Companies:

Roche — Elecsys NfL assay, existing AD pipeline
Quanterix — Simoa platform, biomarker expertise
Biogen — Neurodegeneration focus, [lecanemab](/entities/lecanemab) experience
Alnylam — siRNA delivery, potential NfL-targeted intervention

Budget: $13.8M

Phase 3: Registrational Trial (Months 30-60)

| Milestone | Timeline | Budget | Key Deliverables |
|-----------|----------|--------|------------------|
| FDA/EMA alignment | Months 30-36 | $1.2M | Surrogate endpoint qualification |
| Enriched trial | Months 36-54 | $28M | NfL-stratified registrational trial |
| NDA submission | Months 54-60 | $3.5M | BLA/MAA filing |

Partner Companies (expanded):

Eli Lilly — [Donanemab](/entities/donanemab) experience, biomarker-driven trials
AbbVie — Neuroscience pipeline, BDNF programs
UCB Pharma — Rare neurology, biomarker companion diagnostics

Budget: $32.7M

Total Timeline and Budget

| Phase | Duration | Total Budget |
|-------|----------|--------------|
| Phase 1 | 18 months | $7.5M |
| Phase 2 | 21 months | $13.8M |
| Phase 3 | 30 months | $32.7M |
| Total | 69 months (~5.75 years) | $54M |

Risk Assessment Matrix

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| NfL threshold not predictive | Medium | High | Robust statistical validation, multiple disease cohorts |
| Assay variability across labs | High | Medium | Central lab requirement, assay harmonization protocol |
| Regulatory不接受 biomarker endpoint | Medium | High | Early FDA/EMA engagement, surrogate pathway documentation |
| Enrollment challenges | High | Medium | Multi-site global trial, patient advocacy partnership |
| Competition from competing biomarkers (p-tau) | Medium | Medium | Multi-marker panel approach, head-to-head validation |
| Funding gaps | Medium | High | Phased funding, pharma partnerships at each phase gate |
| Clinical site capacity | Low | Medium | Academic center consortium, dedicated research coordinators |

Regulatory Strategy

FDA Pathway:

Type B Meeting (Month 15): Propose NfL as enrichment biomarker
Fast Track Designation (Month 20): Based on unmet need in AD/PD/ALS
Accelerated Approval (Month 54): NfL trajectory as surrogate endpoint
Full Approval (Month 60): Clinical outcome confirmation

EMA Strategy:

PRIME Designation (Month 18): For ALS indication first
Adaptive Pathways: Iterative data submission
Companion Diagnostic: Co-development with assay partner

Biomarker Qualification:

Submit to [FDA Biomarker Qualification Program](https://www.fda.gov/drugs/biomarker-qualification-program/biomarker-qualification-program)
Build evidence dossier: clinical validation, analytical validation, clinical utility
Target: Enrichment biomarker qualification (not full surrogate)

Key Regulatory Contacts:

FDA CDER: Neurology Division, Office of Neuroscience
EMA: Committee for Medicinal Products for Human Use (CHMP)

Key Milestone Gates

Gate 1 (Month 18): Threshold validation complete → Proceed to intervention study

Gate 2 (Month 30): Interim analysis positive → Proceed to registrational trial

Gate 3 (Month 54): Phase 3 efficacy confirmed → Submit regulatory filings

Next Steps

Immediate Actions (0-6 months)

Threshold validation study: Analyze existing NfL data from ADNI, PPMI, and PROOF cohorts to establish age-adjusted NfL thresholds for treatment response.

Assay standardization: Work with Quanterix and other vendors to harmonize NfL measurements across platforms.

Regulatory strategy: Schedule FDA Type B meeting to discuss biomarker-driven enrichment design.

Research Gaps

Validate NfL threshold specificity for different intervention mechanisms
Establish relationship between plasma vs. CSF NfL for CNS-specific effects
Assess NfL trajectory modeling for individualized treatment windows

Clinical Development Path

Observational study: Establish baseline NfL trajectories in target populations (n=500)

Phase 2: Enrichment trial using NfL threshold for patient selection

Phase 3: Biomarker-stratified registration trial

Academic Partners

Karolinska Institutet (Dr. K. Blennow — biomarker expertise)
University of Gothenburg (Swedish BioFINDER)
Washington University (DIAN-TU)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 7/10/10 | NFL biomarker is established; threshold-based dosing is innovative |
| Mechanistic Rationale | 6/10/10 | Uses biomarker for treatment guidance; addresses axonal injury monitoring |
| Addresses Root Cause | 6/10/10 | Optimizes therapy based on biomarker response; indirect disease modification |
| Delivery Feasibility | 7/10/10 | Standard delivery; biomarker drives treatment decisions |
| Safety Plausibility | 7/10/10 | Enhanced monitoring; early detection of toxicity |
| Combinability | 7/10/10 | Compatible with neuroprotective and disease-modifying therapies |
| Biomarker Availability | 9/10/10 | NFL well-validated; accessible via blood and CSF |
| De-risking Path | 7/10/10 | Threshold-based approach can be validated in trials |
| Multi-disease Potential | 7/10/10 | Relevant for AD, PD, ALS, MS, traumatic brain injury |
| Patient Impact | 7/10/10 | Could optimize therapeutic benefit while minimizing risk |
| Total | 70/100 | |

Cross-Links

Diseases

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[ALS](/diseases/amyotrophic-lateral-sclerosis)
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)
[Multiple Sclerosis](/diseases/multiple-sclerosis)
[Neurodegeneration](/diseases/neurodegeneration)

Mechanisms

[Axonal Degeneration](/mechanisms/axonal-degeneration)
[Neurodegeneration Mechanisms](/mechanisms)
Biomarker Dynamics
[Neuroprotection](/mechanisms/neuroprotection)
[Disease Progression](/diseases/disease-progression)
Therapeutic Threshold

Proteins & Genes

[NfL](/genes/nfl)
[Neurofilament Light Chain](/biomarkers/neurofilament-light-chain)
[NfH](/genes/nfh)
[NfM](/genes/nfm)
[APP](/genes/app)
[Tau](/proteins/tau)
[Alpha-Synuclein](/proteins/alpha-synuclein)

Cell Types

[Neurons](/cell-types/neurons)
Axons
[Motor Neurons](/cell-types/motor-neurons)
[Dopaminergic Neurons](/entities/dopaminergic-neurons)

Treatments

[Biomarker-Guided Therapy](/biomarkers)
Neuroprotective Therapy
Preventive Therapy
[Small Molecule Therapy](/therapeutics)
[Antibody Therapy](/therapeutics/antibody-therapy)

Additional Topics

[CSF Biomarkers](/biomarkers)
[Blood Biomarkers](/biomarkers)
Axonal Damage
[Disease Progression](/diseases/disease-progression)
[Clinical Trials](/clinical-trials)
Personalized Medicine

References

[Mattsson P, Zetterberg H, Janelidze S, et al, NFL in the CSF as a biomarker of neurodegeneration in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26762280/)

[Bacioglu M, Maia LF, Preische O, et al, Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases (2016)](https://pubmed.ncbi.nlm.nih.gov/27452858/)

[Khalil M, Teunissen CE, Otto M, et al, Neurofilaments as biomarkers in neurological disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29527938/)

[Benatar M, Wuu J, Andersen PM, et al, Neurofilament light: A prognostic biomarker in amyotrophic lateral sclerosis (2020)](https://pubmed.ncbi.nlm.nih.gov/32040167/)

[Parnetti L, Gaetani L, Eusebi P, et al, CSF and blood biomarkers for neurodegenerative disease diagnosis (2019)](https://pubmed.ncbi.nlm.nih.gov/31134189/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Senescent Microglia Resolution via Maresins-Senolytics Combination](/hypothesis/h-3f02f222) — 0.72 · Target: BCL2L1
[Targeted Butyrate Supplementation for Microglial Phenotype Modulation](/hypothesis/h-3d545f4e) — 0.72 · Target: GPR109A
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflammatory Priming](/hypothesis/h-f3fb3b91) — 0.67 · Target: TLR4
[Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication](/hypothesis/h-a4e259e0) — 0.65 · Target: CHRNA7
[Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding](/hypothesis/h-8b7727c1) — 0.64 · Target: CSGA

Related Analyses:

[Immune atlas neuroinflammation analysis in neurodegeneration](/analysis/SDA-2026-04-02-gap-immune-atlas-neuroinflam-20260402) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225149) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving NfL-Guided Neuroprotection Threshold discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

ideas-biomarker-nfl-neuroprotection-threshold

▸Metadataorigin_type: v1_polymorphic_backfill

slug	ideas-biomarker-nfl-neuroprotection-threshold
kg_node_id	None
entity_type	idea
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-43fd975ac15d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'ideas-biomarker-nfl-neuroprotection-threshold'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

22

Outgoing

59

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NfL-Guided Neuroprotection Threshold

NfL-Guided Neuroprotection Threshold Therapy

Overview

Rationale

NfL-Guided Neuroprotection Threshold Therapy

Overview

Rationale

Evidence Base

Preclinical Evidence

Clinical Evidence

Clinical Trials

Gaps and Future Needs

Phase 1: Baseline Establishment

Phase 2: Threshold-Guided Intervention

Phase 3: Adaptive Management

Biomarker Readouts

De-risking Path

Phase 2a: Threshold Validation

Active NfL Clinical Trials

Phase 2b: Intervention Study

Phase 3: Confirmatory

Disease Coverage

Combination Potential

Rubric Scoring

Risks and Mitigation

Key Risks

Timeline

Estimated Cost

Key Academic Centers

Potential Partner Companies

Actionable Next Steps

Immediate (3 months)

Near-term (6 months)

Platform (12+ months)

Implementation Roadmap

Phase 1: Threshold Validation (Months 1-18)

Phase 2: Intervention Study (Months 15-36)

Phase 3: Registrational Trial (Months 30-60)

Total Timeline and Budget

Risk Assessment Matrix

Regulatory Strategy

Key Milestone Gates

Next Steps

Immediate Actions (0-6 months)

Research Gaps

Clinical Development Path

Academic Partners

See Also

External Links

Rubric Score

Cross-Links

Diseases

Mechanisms

Proteins & Genes

Cell Types

Treatments

Additional Topics

References

Related Hypotheses

Pathway Diagram

💬 Discussion